Buloxibutid

N/A

Report date: 2024/05/21 11:13:31
NME

Base Information

Drug NameBuloxibutid
Drug Alias NameVP01M-024C-21VP-01C21 +[6] 
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionAngiotensin II receptor type 2 agonists
TargetsAngiotensin II receptor type 2
Therapy Area/IndicationsCoronavirus Disease 2019 (COVID-19)Scleroderma, SystemicRaynaud Disease +[4] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCzechiaBelgiumCanada +[22] 
CombinationsNo
Global Highest StatusPhase 3 Clinical
Highest Status in ChinaN/A
Originator CompaniesVicore Pharma
China Registration ClassN/A

Develop Information

Active CompaniesVicore Pharma AbNippon Shinyaku Co Ltd
Inactive CompaniesN/A
Active IndicationsCoronavirus Disease 2019 (COVID-19)Idiopathic Pulmonary Fibrosis
Inactive IndicationsScleroderma, SystemicRaynaud Disease

Other Information

ATC CodeN/A
Related LinksDrugBank